Alector, Inc. (NASDAQ:ALEC) Receives $3.75 Consensus Target Price from Analysts

Alector, Inc. (NASDAQ:ALEC) has been given an average rating of “Hold” by the seven ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $3.50.

A number of research firms recently issued reports on ALEC. BTIG Research lowered their target price on shares of Alector from $16.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, November 26th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alector in a research note on Tuesday, November 26th. HC Wainwright restated a “buy” rating and issued a $7.00 price target on shares of Alector in a research report on Thursday, February 27th. Morgan Stanley restated an “underweight” rating and issued a $1.50 price target (down from $3.00) on shares of Alector in a research report on Friday. Finally, Stifel Nicolaus lowered shares of Alector from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a research report on Monday, December 16th.

Institutional Trading of Alector

Several institutional investors have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Alector by 1.0% during the 3rd quarter. FMR LLC now owns 14,595,014 shares of the company’s stock valued at $68,013,000 after acquiring an additional 137,794 shares in the last quarter. RA Capital Management L.P. acquired a new stake in shares of Alector during the 4th quarter valued at about $18,324,000. JPMorgan Chase & Co. boosted its position in shares of Alector by 64.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,728,823 shares of the company’s stock valued at $12,716,000 after acquiring an additional 1,072,298 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Alector by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 1,914,250 shares of the company’s stock valued at $3,619,000 after acquiring an additional 10,308 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C boosted its position in shares of Alector by 1.1% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 1,066,962 shares of the company’s stock valued at $2,017,000 after acquiring an additional 11,770 shares in the last quarter. 85.83% of the stock is currently owned by institutional investors and hedge funds.

Alector Stock Performance

Shares of NASDAQ:ALEC opened at $1.44 on Thursday. The stock has a market capitalization of $142.68 million, a price-to-earnings ratio of -0.85 and a beta of 0.65. Alector has a 1-year low of $1.30 and a 1-year high of $6.97. The company has a 50 day moving average price of $1.74 and a 200 day moving average price of $3.37.

Alector (NASDAQ:ALEC) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.59. Alector had a negative net margin of 257.54% and a negative return on equity of 108.77%. The business had revenue of $54.24 million for the quarter, compared to the consensus estimate of $20.41 million. On average, sell-side analysts expect that Alector will post -1.88 EPS for the current fiscal year.

Alector Company Profile

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.